Health Workers in DR Congo Begin Testing Ebola Vaccine Amid Severe Outbreak
Frontline health personnel in the Democratic Republic of Congo have begun receiving an experimental vaccine deployment to test cross-protection against an unapproved strain in the country's worst-ever Ebola epidemic.
Health workers operating within heavily impacted regions of the Democratic Republic of Congo have launched a test vaccination programme to evaluate whether jabs designed for an alternative strain of the virus can offer protection during the ongoing epidemic. According to reports from the region published on September 20, 2026, the vaccination effort began on Saturday, targeting frontline medical personnel.
The initiative is supported by key international and medical bodies, including the World Health Organization and the Doctors Without Borders charity, commonly known as MSF. Under the framework of the study, which is expected to last for a duration of up to a year, approximately 20,000 frontline health workers are slated to receive the Ervebo vaccination across the Ituri and North-Kivu provinces.
Official figures from Congolese authorities place the human toll of the current epidemic at 3,639 fatalities out of a total of 7,541 confirmed cases. This translates to a severe fatality rate of roughly 48.3%. According to statements from the country's health minister cited in reporting by Agence France-Presse, the ongoing crisis represents the country's worst Ebola outbreak on record.
The health emergency is driven specifically by the Bundibugyo strain of the virus. Medical authorities note that there is currently no approved vaccine or specific medical treatment officially cleared for the Bundibugyo variant.
Conversely, the vaccination being administered in the weekend rollout was originally developed to combat the Zaire strain of Ebola. The primary objective of the new study is to determine the extent of effectiveness this alternative vaccine might demonstrate when deployed against the Bundibugyo strain.
Steve Ahuka, a Congolese official participating in the national health task force responding to the outbreak, highlighted the scientific uncertainty surrounding the trial. He noted that officials do not yet know to what exact degree the vaccine might prove effective against the specific strain driving the current epidemic.
Adding to this perspective, Nana Mimbu, a research coordinator for Doctors Without Borders, suggested that the intervention could potentially offer a certain level of cross-protection against the Bundibugyo virus.
Regarding the operational logistics, the United Nations health agency announced the previous month that a total of 70,000 doses of the vaccine—developed by pharmaceutical firm Merck and manufactured in Germany—were scheduled for delivery to the Democratic Republic of Congo. Journalists on the ground in Bunia, the main urban center of Ituri province, observed local health workers receiving their vaccinations at a designated centre.
Assessments of the broader epidemiological situation remain complex. World Health Organization officials have pointed to certain encouraging signs indicating that transmission rates may be slowing down across affected territories. However, Doctors Without Borders issued a contrasting assessment, cautioning that clear evidence demonstrating the epidemic is firmly coming under control is still lacking.
Meanwhile, the geographic footprint of the crisis has continued to expand. Recent updates indicate that the outbreak in eastern Congo has extended its reach into two additional health zones, bringing the total number of affected areas across the region to 60.
World Health Organization experts have pointed to early data, notably findings derived from animal trials, suggesting that the Ervebo vaccine could indeed supply a degree of protection amidst the current public health emergency. The ongoing year-long study in Ituri and North-Kivu provinces is expected to provide definitive real-world data regarding its cross-strain efficacy.